Zentalis' Azenosertib Shows Promising Results in Ovarian Cancer Trial
Event summary
- Zentalis Pharmaceuticals will present Phase 1b MUIR trial data at ASCO 2026, showing a 39% ORR and 7.3-month median PFS for azenosertib plus paclitaxel in platinum-resistant ovarian cancer.
- The 250 mg QD 5:2 intermittent dose cohort achieved a 50% ORR and 9.2-month median DOR.
- The trial included 46 patients across four dose cohorts, with a manageable safety profile and low frequency of high-grade adverse events.
- Data suggests Cyclin E1 status may not be as important in the combination setting.
The big picture
Zentalis is positioning azenosertib as a potential first-in-class WEE1 inhibitor with broad applicability across multiple tumor types. The Phase 1b MUIR trial results suggest the drug could expand beyond its current focus on Cyclin E1-positive platinum-resistant ovarian cancer, potentially unlocking larger market opportunities. The manageable safety profile and encouraging clinical activity support Zentalis' strategy of advancing azenosertib in combination therapies, which could differentiate it in the competitive oncology space.
What we're watching
- Dose Optimization
- Whether the 250 mg intermittent dose will be confirmed as the optimal therapeutic index for further studies.
- Biomarker Relevance
- How the apparent lack of Cyclin E1 dependency in the combination setting will impact future trial designs.
- Combination Strategy
- The pace at which Zentalis can advance azenosertib-taxane combinations in broader ovarian cancer settings and other tumor types.
Related topics